Our Commitment to Product Compliance and Safety
Since our establishment in July 2019, we have continuously strived to set the highest UK standards and be a fully regulatory-compliant and responsible company.
We have ensured the safety and quality of our CBD products by engaging with the Food Standards Agency and the Novel Foods regulatory process. All our ingestible CBD products are on the current FSA list and linked to a submitted Novel Foods application containing all the necessary safety, testing, and research documentation.
Additionally, we conduct batch testing via an independent UK, ISO-accredited laboratory and provide customers with a Certificate of Analysis (CoA) for each product.
Status of Our Novel Foods Application
Beliebis submitted two novel foods applications to the FSA before the 31st March 2021 deadline. Our products are linked to two applications under the primary ingredient manufacturer's application.
One of them (RP427) has already been validated by the FSA.
The other (RP349) has now also been validated.
You can view our products on the FSA's list of CBD products linked to credible Novel Food applications here.
Adhering to Legal Requirements and Guidelines
At Beliebis, we ensure that our products meet the legal THC levels in the UK through batch testing conducted at an independent, ISO-accredited laboratory. We also provide our customers with a copy of the product's Certificate of Analysis for your peace of mind and quality assurance.
Our editor approves all published content to ensure no unfounded health claims are made. We adhere to the UK's strict labelling guidelines, including those warnings and recommendations on our product pages.
Engaging with Industry Associations, Self-Regulation and Ongoing Efforts to Ensure High-Quality CBD Products
Beliebis is part of the EIHA consortium Novel Food application and actively participates in self-regulatory initiatives within the industry.
As part of the EIHA consortium, we have invested in research to improve the safety and development of CBD products.
Please stay up to date and follow our progress by visiting this page. Alternatively, if you have any questions, please do not hesitate to contact us below for further information.
